<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Supportive Therapy in Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Supportive Therapy in Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Поддерживающая терапия в онкологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">3034-2473</issn><issn publication-format="electronic">3034-3178</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">14</article-id><article-id pub-id-type="doi">10.17650/3034-2473-2024-1-2-14-22</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Study of the use of La Roche-Posay Dermatological Laboratory skincare products for radiodermatitis prevention and treatment</article-title><trans-title-group xml:lang="ru"><trans-title>Исследование применения косметических средств Дерматологической лаборатории La Roche-Posay в рамках профилактики и лечения радиодерматита</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9106-5277</contrib-id><name-alternatives><name xml:lang="en"><surname>Balaeva</surname><given-names>D. A.</given-names></name><name xml:lang="ru"><surname>Балаева</surname><given-names>Д. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><!--StartFragment --></p><p>Dayana Arsenovna Balaeva</p><p>2 Budayskaya St., Moscow 129128</p><p>Build. 1, 20 Delegatskaya St., Moscow 127473</p></bio><bio xml:lang="ru"><p>Даяна Арсеновна Балаева</p><p>129128 Москва, ул. Будайская, 2</p><p>127473 Москва, ул. Делегатская, 20, стр. 1</p></bio><email>daianakhlanta@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-7743-7355</contrib-id><name-alternatives><name xml:lang="en"><surname>Garyaev</surname><given-names>G. A.</given-names></name><name xml:lang="ru"><surname>Гаряев</surname><given-names>Г. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>2 Budayskaya St., Moscow 129128</p><p>Build. 1, 2/1 Barrikadnaya St., Moscow 125993</p></bio><bio xml:lang="ru"><p>129128 Москва, ул. Будайская, 2</p><p>125993 Москва, ул. Баррикадная, 2/1, стр. 1</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0042-1150</contrib-id><name-alternatives><name xml:lang="en"><surname>Ter-Ovanesov</surname><given-names>M. D.</given-names></name><name xml:lang="ru"><surname>Тер-Ованесов</surname><given-names>М. Д.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Build. 1, 20 Delegatskaya St., Moscow 127473</p></bio><bio xml:lang="ru"><p>127473 Москва, ул. Делегатская, 20, стр. 1</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3942-4102</contrib-id><name-alternatives><name xml:lang="en"><surname>Romanov</surname><given-names>D. S.</given-names></name><name xml:lang="ru"><surname>Романов</surname><given-names>Д. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>2 Budayskaya St., Moscow 129128</p><p>Build. 1, 20 Delegatskaya St., Moscow 127473</p><p>22b Dukhovsky Lane, Moscow 115191</p></bio><bio xml:lang="ru"><p>129128 Москва, ул. Будайская, 2</p><p>127473 Москва, ул. Делегатская, 20, стр. 1</p><p>115191 Москва, Духовской пер., 22б</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4818-0093</contrib-id><name-alternatives><name xml:lang="en"><surname>Gorchak</surname><given-names>Yu. Yu.</given-names></name><name xml:lang="ru"><surname>Горчак</surname><given-names>Ю. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Build. 1, 20 Delegatskaya St., Moscow 127473</p></bio><bio xml:lang="ru"><p>127473 Москва, ул. Делегатская, 20, стр. 1</p></bio><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Central Clinical Hospital “RZD-Medicine”</institution></aff><aff><institution xml:lang="ru">УЗ «Центральная клиническая больница «РЖД-Медицина»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Russian University of Medicine, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Российский университет медицины» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Center for Innovative Medical Technologies</institution></aff><aff><institution xml:lang="ru">ООО «Центр инновационных медицинских технологий»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-07-15" publication-format="electronic"><day>15</day><month>07</month><year>2024</year></pub-date><volume>1</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>14</fpage><lpage>22</lpage><history><date date-type="received" iso-8601-date="2024-10-02"><day>02</day><month>10</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-10-02"><day>02</day><month>10</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Balaeva D.A., Garyaev G.A., Ter-Ovanesov M.D., Romanov D.S., Gorchak Y.Y.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Балаева Д.А., Гаряев Г.А., Тер-Ованесов М.Д., Романов Д.С., Горчак Ю.Ю.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Balaeva D.A., Garyaev G.A., Ter-Ovanesov M.D., Romanov D.S., Gorchak Y.Y.</copyright-holder><copyright-holder xml:lang="ru">Балаева Д.А., Гаряев Г.А., Тер-Ованесов М.Д., Романов Д.С., Горчак Ю.Ю.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://stio.abvpress.ru/jour/article/view/14">https://stio.abvpress.ru/jour/article/view/14</self-uri><abstract xml:lang="en"><p>Risks of adverse effects during therapy increase along with progress in oncology and development of new treatment methods. Thus, radiotherapy, one of the main methods of treatment of malignant tumors of various locations, can cause radiodermatitis: an adverse side effect manifesting on the skin in the irradiated area or near it. Clinical manifestations vary from stage to stage and negatively affect patients’ willingness to undergo or continue treatment due to fear of esthetic defects of the skin. Additionally, development of advanced stage radiodermatitis carries the risk of infectious complications in this area. One of the goals of radiation therapists is management of radiation-induced dermatitis and search for techniques aimed at its treatment and prevention.</p><p>This study evaluates the effects of several products and their components on clinical manifestations of radiodermatitis caused by radiation therapy.</p></abstract><trans-abstract xml:lang="ru"><p>Вместе с развитием онкологии, разработкой новых методов лечения увеличиваются риски возникновения нежелательных эффектов в ходе терапии. Так, в результате применения радиотерапии, представляющей один из основных методов лечения злокачественных новообразований различных локализаций, возможно развитие радиодерматита – нежелательного побочного эффекта, проявляющегося на кожных покровах непосредственно в зоне облучения или вблизи нее. Формы клинических проявлений различны от стадии к стадии и оказывают неблагоприятное влияние на готовность пациентов к проведению лечения, его продолжению, появление опасений в отношении возникновения эстетических дефектов кожных покровов. Кроме того, развитие радиодерматита до запущенных стадий влечет за собой риски инфекционных осложнений данной области. Одна из задач радиотерапевтов – борьба с радиоиндуцированным дерматитом и поиск средств, направленных на его профилактику и лечение. В настоящем исследовании оценено влияние некоторых средств и их компонентов на клинические проявления радиодерматита, возникающего при проведении лучевой терапии.</p></trans-abstract><kwd-group xml:lang="en"><kwd>radiotherapy</kwd><kwd>radiodermatitis</kwd><kwd>triterpene</kwd><kwd>superoxide dismutase</kwd><kwd>nicotinamide</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>лучевая терапия</kwd><kwd>радиодерматит</kwd><kwd>тритерпен</kwd><kwd>супероксиддисмутаза</kwd><kwd>никотинамид</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Pelevina I.I., Petushkova V.V., Biryukov V.A. et al. The “radiation-induced non-targeted effects” and their role in human cell response to low radiation forcing. Radiatsionnaya biologiya. Radioekologiya = Radiation Biology. Radioecology 2019;59(3):261–73. (In Russ.). DOI: 10.1134/S086980311903010X</mixed-citation><mixed-citation xml:lang="ru">Пелевина И.И., Петушкова В.В., Бирюков В.А. и др. Роль «немишенных эффектов» в реакции клеток человека на радиационное воздействие. Радиационная биология. Радиоэкология 2019;59(3):261–73. DOI: 10.1134/S086980311903010X</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><mixed-citation>Schmeell L.C., Koch D., Stumpf S. et al. Prophylactically applied Hydrofilm polyurethane film dressings reduce radiation dermatitis in adjuvant radiation therapy of breast cancer patients. Acta Oncol 2018;57(7):908–15. DOI: 10.1080/0284186X.2018.1441542</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Robijns J., Censabella S., Claes S. et al. Prevention of acute radiodermatitis by photobiomodulation: a randomized, placebo-controlled trial in breast cancer patients (TRANSDERmIS trial). Lasers Surg med 2018;50(7):763–71. DOI: 10.1002/lsm.22804</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Sekiguchi K., Akahane K., Ogita M. et al. Efficacy of heparinoid moisturizer as a prophylactic agent for radiation dermatitis following radiotherapy after breast-conserving surgery: a randomized controlled trial. Jpn J Clin Oncol 2018;48(5):450–7. DOI: 10.1093/jjco/hyy045</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Bontempo P.S.M., Ciol M.A., Menêses A.G. et al. Acute radiodermatitis in cancer patients: incidence and severity estimates. Rev Esc Enferm USP 2021;55:e03676. DOI: 10.1590/S1980-220X2019021703676</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Cox J.D., Stetz J., Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31(5):1341–6. DOI: 10.1016/0360-3016(95)00060-C</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Chan R.J., Webster J., Chung B. et al. Prevention and treatment of acute radiation-induced skin reactions: a systematic review and meta-analysis of randomized controlled trials. BmC Cancer 2014;14:53. DOI: 10.1186/1471-2407-14-53</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Matsuu-Matsuyama M., Nakashima M., Shichijo K. et al. Basic fibroblast growth factor suppresses radiation-induced apoptosis and TP53 pathway in rat small intestine. Radiat Res 2010;174(1):52–61. DOI: 10.1667/RR1802.1</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Roy I., Fortin A., Larochelle M. The impact of skin washing with water and soap during breast irradiation: a randomized study. Radiother Oncol 2001;58(3):333–9. DOI: 10.1016/s0167-8140(00)00322-4</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Gilca M., Tiplica G.S., Salavastru C.m. Traditional and ethnobotanical dermatology practices in Romania and other Eastern European countries. Clin Dermatol 2018;36(3):338–52. DOI: 10.1016/j.clindermatol.2018.03.008</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Messire G., Serreau R., Berteina-Raboin S. Antioxidant effects of catechins (EGCG), andrographolide, and curcuminoids compounds for skin protection, cosmetics, and dermatological uses: an update. Antioxidants (Basel) 2023;12(7):1317. DOI: 10.3390/antiox12071317</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Boo Y.C. Mechanistic basis and clinical evidence for the applications of nicotinamide (niacinamide) to control skin aging and pigmentation. Antioxidants (Basel) 2021;10(8):1315. DOI: 10.3390/antiox10081315</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Madaan P., Sikka P., Malik D.S. Cosmeceutical aptitudes of niacinamide: a review. Recent Adv Antiinfect Drug Discov 2021;16(3):196–208. DOI: 10.2174/2772434416666211129105629</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Xie J., Jia L., Xie P. et al. Efficacy and safety of epigallocatechin-3-gallate in treatment acute severe dermatitis in patients with cancer receiving radiotherapy: a phase I clinical trial. Sci Rep 2023;13(1):13865. DOI: 10.1038/s41598-023-40881-4</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Prades-Sagarra È., Yaromina A., Dubois L.J. Polyphenols as potential protectors against radiation-induced adverse effects in patients with thoracic cancer. Cancers (Basel) 2023;15(9):2412. DOI: 10.3390/cancers15092412</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Mioc M., Milan A., Malița D. et al. Recent advances regarding the molecular mechanisms of triterpenic acids: a review (part I). Int J mol Sci 2022;23(14):7740. DOI: 10.3390/ijms23147740</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Park H.A., Kim M.Y., Lee N.Y. et al. Variation of triterpenic acids in 12 wild Syzygium formosum and anti-inflammation activity on human keratinocyte HaCaT. Plants (Basel) 2021;10(11):2428. DOI: 10.3390/plants10112428</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Shao X., Chen T., Li H. et al. Efficacy of topical steroids in preventing radiation dermatitis: a systematic review and meta-analysis. Dermatol Ther 2022;35(12):e15918. DOI: 10.1111/dth.15918</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Tam S., Zhou G., Trombetta M. et al. Topical corticosteroids for the prevention of severe radiation dermatitis: a systematic review and meta-analysis. Support Care Cancer 2023;31(7):382. DOI: 10.1007/s00520-023-07820-5</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Ho A.Y., Olm-Shipman M., Zhang Z. et al. A randomized trial of mometasone furoate 0.1 % to reduce high-grade acute radiation dermatitis in breast cancer patients receiving postmastectomy radiation [published correction appears in Int J Radiat Oncol Biol Phys 2018;102(1):231]. Int J Radiat Oncol Biol Phys 2018;101(2):325–33. DOI: 10.1016/j.ijrobp.2018.02.006</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Kumar Soni S., Basu M., Agrawal P. et al. Evaluation of gamma radiation-induced biochemical changes in skin for dose assesment: a study on small experimental animals. Disaster med Public Health Prep 2019;13(2):197–202. DOI: 10.1017/dmp.2018.16</mixed-citation></ref></ref-list></back></article>
